What is psychedelic therapy? Guide to healing & mental health

TL;DR:

• Psychedelic therapy is a research model that pairs a psychedelic compound, such as psilocybin or MDMA, with structured psychotherapy. In the US these compounds are investigational and available only in clinical trials.
• The research model has three phases: preparation, a supervised session, and integration.
• The only related treatments available in clinics today are Spravato (esketamine), which is FDA-approved for depression, and ketamine, which is prescribed off-label.

Most people hear the words “psychedelic therapy” and picture something far outside a doctor’s office. The research picture is quite different. Psychedelic therapy describes the study of compounds such as psilocybin and MDMA, given under close clinical supervision alongside psychotherapy, for conditions like depression, PTSD and substance use disorders. This guide explains what psychedelic therapy is, how the research model works, what the studies show so far, the real risks and open questions, and what is and is not available to patients today.

Key Takeaways

1. 01

   Mostly investigational

   Psilocybin, MDMA, LSD and DMT are not FDA-approved treatments; in the US they are given only in clinical trials.

2. 02

   Structure is part of the model

   Research protocols build in preparation and integration, not just the session itself.

3. 03

   Evidence is promising but early

   Trials suggest benefit for some conditions, with real limits on blinding, sample size and long-term data.

4. 04

   Know the risks and fit

   Some people, including those with a history of psychosis or bipolar disorder, are excluded from trials for safety.

What is psychedelic therapy? Defining the basics

At its core, psychedelic therapy is the research use of psychedelic compounds, such as psilocybin, MDMA, LSD and DMT, within a structured therapeutic protocol. In trials, every session takes place under clinical supervision, with trained therapists present from start to finish, after careful medical and psychiatric screening.

The conditions being studied are serious and often hard to treat. They include:

• Depression, including major depressive disorder and treatment-resistant forms
• Anxiety and distress, including existential distress in serious illness
• PTSD (post-traumatic stress disorder)
• Substance use disorders, including alcohol use disorder

Some of these substances have long histories in Indigenous traditions. Clinical research began in the 1950s and 1960s, largely stopped after the substances were placed under strict federal control, and has returned over the past two decades at institutions such as Johns Hopkins and NYU.

Legally, psilocybin, MDMA, LSD and DMT remain Schedule I substances under US federal law. A few states have created their own regulated programs for psilocybin, but none of these compounds is an FDA-approved medical treatment. Ketamine is different: it is an approved anesthetic that doctors can prescribe off-label for depression, and its close relative esketamine (Spravato) is FDA-approved for treatment-resistant depression.

If you are curious about alternative therapies for emotional healing beyond conventional medications, it helps to keep these categories separate: approved, off-label and investigational.

Now that we’ve covered the basics, let’s look at how the research model is structured.

How psychedelic therapy works: The three key phases

What separates the psychedelic therapy model from a simple prescription is its structured, relational process. Research protocols typically involve three phases: preparation, the supervised session, and integration.

Here is what each phase looks like in a typical study:

1. Preparation. Participants meet the study therapists several times before any session. This is about building rapport, reviewing history and setting clear intentions.
2. Supervised session. The compound is given in a clinical setting, and trained staff stay present to monitor and support. Participants are not left alone.
3. Integration. Afterwards, participants work with their therapists to make sense of what came up and how it relates to daily life.

The same three-part structure is used in ketamine-assisted psychotherapy, which is available today: preparation with a therapist, a supervised ketamine session, and integration sessions afterwards.

Exploring holistic therapy benefits can help you understand why whole-person care often pairs medication with therapy. With the process in mind, let’s look at what the research shows.

Evidence and effectiveness: What does research show?

The research has moved beyond small pilot studies, and some results are encouraging. It is still early, and the findings come with real caveats.

For depression, several randomized trials of psilocybin with psychological support have reported meaningful short-term reductions in symptoms compared with control conditions, and the FDA has given psilocybin “breakthrough therapy” designation to speed its study. That designation is not an approval. Larger phase 3 trials are still underway, and how psilocybin compares with established treatments over the long term is not yet known.

For PTSD, MDMA-assisted therapy reached phase 3 trials. In August 2024, the FDA declined to approve it and asked for an additional phase 3 study, citing concerns that included trial design and how safety data were collected. MDMA remains investigational.

DMT has also entered clinical research. An early phase IIa randomized controlled trial in major depressive disorder reported greater reductions in depression scores than placebo, but this is early-stage evidence in a small group.

Here is a simplified comparison of the main compounds:

For a broader look at psycho-spiritual approaches to healing, it helps to start from this map of what is approved, what is off-label and what is still being studied.

Risks, safety, and controversies in psychedelic therapy

Honesty matters here. These compounds carry real risks, and their effects on the mind are strong enough to cut both ways.

Trials typically exclude people with a personal or family history of psychosis or bipolar disorder, because psychedelics can trigger or worsen these conditions. Other risks and concerns include:

• Increased psychosis risk in vulnerable individuals
• Rises in blood pressure and heart rate
• Ethical concerns around consent during altered states
• Potential for boundary violations by therapists
• Intense psychological distress during difficult sessions
• Re-traumatization if not properly supported

There are also open debates about therapy integration in the research community. One is whether formal psychotherapy is necessary alongside the compound, or whether the compound alone accounts for the effect. Another is blinding: when a participant receives a high dose of psilocybin, they usually know it, which makes placebo-controlled research hard to design and can inflate results.

Exploring integrative approaches to therapy can help you understand how safety and structure are built into responsible care.

What is available today? Practical steps and considerations

If you are struggling with depression or trauma that has not improved, it is natural to want to know whether any of this is open to you. Here is a practical way to think about it:

1. Start with an assessment. A psychiatric evaluation can clarify your diagnosis and which treatments you have and have not tried. For many conditions, first-line options such as psychotherapy and medication have not been fully explored.
2. Know what is approved. For treatment-resistant depression, Spravato (esketamine) is FDA-approved and given in certified clinics. Ketamine-assisted psychotherapy is offered off-label by some clinics.
3. Treat psilocybin and MDMA as research. Outside a small number of state-regulated programs, the only medical route to these compounds in the US is a registered clinical trial, which you can search for at ClinicalTrials.gov.
4. Be fully honest about your history. Share your full mental health history, including any family history of psychosis or bipolar disorder, with any clinician you see.
5. Ask the right questions. Ask what screening, monitoring and follow-up support are included, and who is responsible for your care between sessions.

What most guides miss: The essential ingredient in psychedelic research

One of the most interesting questions in this field is how much of the benefit comes from the compound and how much from the care around it.

Most conversations focus on the substance. But researchers consistently describe the therapeutic relationship, the preparation and integration work, and the safety of the setting as central parts of the model, and part of the current debate is exactly how much each contributes.

That lesson applies well beyond psychedelics. Whatever treatment you consider, the quality of the people and the structure around it matters a great deal. Psycho-spiritual integration is one way some people think about that work.

If you are considering any new treatment, put as much thought into choosing your care team as into researching the treatment itself.

Explore evidence-based care with Mystic Health

If reading this has stirred something in you, whether curiosity, hope, or a quiet recognition that you are ready for a different kind of care, you do not have to figure out the next step alone.

Mystic Health is a physician-led clinic in Santa Monica, California. We do not offer psilocybin, MDMA or other investigational psychedelics. We do offer Spravato, FDA-approved for treatment-resistant depression and given in our REMS-certified clinic, and ketamine-assisted psychotherapy, which uses ketamine off-label with preparation, a guided session and integration with a therapist. We also offer psychiatry and psychotherapy. You can read the research behind our care in our clinical evidence library, or book a free discovery call with our care team.

Frequently asked questions

Recommended

• Psycho-spiritual therapy: A holistic guide to healing
• Innovative therapies for emotional healing: CBT to psychedelics